Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,029 people get NAVB articles and Market Currents by email alert.
Get email alerts on NAVB »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Business Wire (May 29, 2013)
-
Business Wire (May 15, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 3, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 5, 2013)
-
Business Wire (Apr 3, 2013)
-
Business Wire (Apr 1, 2013)
NAVB vs. ETF Alternatives
Company Description
Currently, there's no company description for NAVB.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, June 12, 9:58 AM Navidea Biopharmaceuticals' (NAVB +3%) announces "positive results" from a meta-analysis study of two Phase III trials that compared its Lymphoseek radiopharmaceutical injection with a commonly used agent. Lymphoseek "demonstrated reliable detection of lymph nodes" in patients with breast cancer and melanoma over a period of 15 minutes up to 30 hours, a time range that may be encountered in a clinic. (PR) 1 Comment [Healthcare]
- Thursday, May 16, 10:16 AM Navidea Biopharmaceuticals (NAVB) says it's entered into an agreement with Nordion (NDZ -1%) to produce and supply its (123) labeled I-drug NAV5001 for late-phase clinical trials. NDZ will manufacture and supply of NAV5001 clinical trial material by radiolabeling NAVB's precursor drug product with Iodine-123 to form (123)I NAV5001, and then manage the logistics and shipping arrangements to third-party clinical trial sites. The agreement could be a precursor to a commercial supply arrangement in the future. Comment! [Healthcare, Global & FX]
- Wednesday, May 8, 7:02 AM Navidea Biopharmacueticals (NAVB): Q1 EPS of -$0.06 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, May 8, 12:05 AM Notable earnings before Wednesday’s open: AOL, ARQL, CTSH, CWH, DTEGY.PK, ENB, EZCH, FSYS, FUN, KRO, LMCA, LSE, MPEL, NAVB, NICE, POZN, SODA, STWD, THI, TTI, VVUS, WEN, WMC Comment! [Earnings]
- Tuesday, May 7, 5:30 PM Notable earnings before Wednesday’s open: AOL, ARQL, CTSH, CWH, DTEGY.PK, ENB, EZCH, FSYS, FUN, KRO, LMCA, LSE, MPEL, NAVB, NICE, POZN, SODA, STWD, THI, TTI, VVUS, WEN, WMC Comment! [Earnings]
-
Wednesday, May 1, 9:10 AM
Premarket gainers: IQNT +34%. MSPD +31%. TRLA +14%. FIRE +12%. JRCC +11%. CAAS +8%. DWA +9%. GDOT +8%. CAVM +8%. NAVB +5%.
Losers: HIMX -9%. ELGX -8%. SWI -8%. Comment! [On the Move] - Wednesday, May 1, 12:10 AM Notable earnings after Wednesday’ s close: ALL, ARI, ARR, ATML, ATO, ATW, AXLL, AXTI, BKD, BMR, CACI, CAR, CBS, CJES, CNQR, CSOD, CVD, CVI, CVRR, CWT, CXO, DVR, DX, DXCM, DXPE, EDMC, ESS, EXPD, EXXI, FB, FNF, FRT, G, GLUU, GNK, GTAT, HNSN, HR, IPI, IPXL, IVR, JDSU, KIM, LNC, LOCK, LVS, MAC, MAR, MET, MUR, NAVB, NGD, NLY, NTRI, PHH, POL, PRU, PSE, PXD, QUIK, ROVI, SAM, SFLY, SGMO, SLTM, SNCR, STX, TEG, TGI, TPC, TSO, TTEK, UAN, UNM, V, VVC, WES, WLT, YELP Comment! [Earnings]
- Tuesday, April 30, 5:35 PM Notable earnings after Wednesday’ s close: ALL, ARI, ARR, ATML, ATO, ATW, AXLL, AXTI, BKD, BMR, CACI, CAR, CBS, CJES, CNQR, CSOD, CVD, CVI, CVRR, CWT, CXO, DVR, DX, DXCM, DXPE, EDMC, ESS, EXPD, EXXI, FB, FNF, FRT, G, GLUU, GNK, GTAT, HNSN, HR, IPI, IPXL, IVR, JDSU, KIM, LNC, LOCK, LVS, MAC, MAR, MET, MUR, NAVB, NGD, NLY, NTRI, PHH, POL, PRU, PSE, PXD, QUIK, ROVI, SAM, SFLY, SGMO, SLTM, SNCR, STX, TEG, TGI, TPC, TSO, TTEK, UAN, UNM, V, VVC, WES, WLT, YELP 2 Comments [Earnings]
- Thursday, April 18, 2:12 PM Navidea Biopharmaceuticals (NAVB -1.5%) says results from a clinical trial of NAV4694 in healthy subjects and those with diagnosed forms of dementia demonstrated imaging characteristics nearly identical to those of an acknowledged benchmark, gold-standard amyloid imaging agent, 11C-labeled Pittsburgh Compound-B. The authors believe these results show that NAV4694 may be useful in the early and differential diagnosis of Alzheimer’s disease. Comment! [Healthcare, On the Move]
-
Wednesday, April 17, 5:45 PM
After-hours top gainers, as of 5:15 p.m.: CONE +9%. SLCA +4%. MXIM +4%. LNC +4%. MHR +3%.
After-hours top losers: SCSS -7%. CCK -4%. SNDK -3%. NAVB -3%. EBAY -2%. Comment! [On the Move] -
Tuesday, April 9, 5:56 PM
After-hours top gainers, as of 5:15 p.m.: ACTS +8%. PSUN +6%. PZE +5%. PSMT +4%. NAVB +3%.
After-hours top losers: SGYP -12%. HMA -11%. SEAC -10%. RLGY -7%. THC -5%. Comment! [On the Move] -
Thursday, April 4, 9:10 AM
Premarket gainers: CBMX +20%. PSDV +13%. NAVB +10%. ALU +9%. ARIA +6%.
Comment! [On the Move] - Thursday, April 4, 8:20 AM Navidea Biopharmaceuticals (NAVB +7.8%) after saying that its Lymphoseek radiopharmaceutical met its primary endpoint in a Phase III trial by identifying sentinel lymph nodes in patients with squamous cell carcinoma (skin cancer) of the head or in the mouth, Until now, expensive surgery has been used. Following the results, the study's Data Safety Monitoring Committee has recommended that Navidea close the trial early. (PR) Comment! [Healthcare, On the Move]
- Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]
- Wednesday, March 27, 12:04 PM Navidea Biopharmaceuticals (NAVB +0.8%) bucks a weak tape after saying it's commenced enrollment in Phase 2b positron emission tomography imaging studies of NAV4694, a scan for detecting cerebral-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment. The study is designed to investigate whether scan findings have the ability to distinguish between subjects with MCI who progress to Alzheimer's disease from those who do not. 1 Comment [Healthcare, On the Move]
- Thursday, March 21, 9:40 AM Navidea Biopharmaceuticals' (NAVB +2.2%) Lymphoseek radiopharmaceutical for identifying tumors met the efficacy primary endpoint in two Phase III trials. Lymphoseek, which has been approved by the FDA, demonstrated its "utility and safety" in patients with breast cancer. (PR) 3 Comments [Healthcare]
-
- View all 0 replies
-
- View all 1 replies
-
-
oneotherfool
$NAVB CEO to provide an update of the Company and its development programs April 5 at the Future Leaders in the Biotech Industry Conference - View all 0 replies
-
oneotherfool
$NAVB Price as of Thursday close 3/28/13 is $2.71 according to Nasdaq. The displayed value of $2.66 is wrong, or am I missing something? - View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 15 replies
-
-
LEIGHDIST: im still in amrn also waiting for nce this week hopefully, have you heard anything
-
- View all 0 replies
-
John McCoy
$NAVB up 10% this week, closing today at $3.29. Looks to be starting it's run up to PDUFA date. - View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
oneotherfool
$NAVB Price as of Thursday close 3/28/13 is $2.71 according to Nasdaq. The displayed value of $2.66 is wrong, or am I missing something? - View all 1 replies
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 15 replies
-
-
LEIGHDIST: im still in amrn also waiting for nce this week hopefully, have you heard anything
-
- View all 12 replies
-
-
-
Scott Matusow
$NAVB fail, those who listen to my show on a reg basis know I have never liked management there. - View all 3 replies
-
thsearfoss: With that said, do you see a potential opportunity if they figure this road block out?
-
-
- View all 2 replies
-
reachmygoals1: large blocks of buys friday sept 7, lets see if this continues into monday or halt for fda decision. good luck to all holding NAVB
-
-
- View all 7 replies
-
Manuel Pastore: Stock will rally all of next week prior to the PDUFA date, now is a great entry before the run! -
Manuel Pastore: If approved, is definitely breaking into new, never seen highs! for the company of course.
-
- View all 1 replies
-